The dismissal of a proposed class action targeting NIVEA owner Beiersdorf AG in California's Southern District should help to discourage suits against cosmetic skin-care brands based on plaintiffs' interpretations of FDA's "drug" definition and marketing requirements.
That's assuming that the federal court's April 4 order holds up on appeal in the US Ninth Circuit
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?